Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
obesity drug
Advertisement
Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
Zealand Pharma Showcases Petrelintide Obesity Data
COPENHAGEN, Denmark, May 27, 2026 Zealand Pharma announced that new clinical data from its obesity and metabolic disease pipeline...
Caliway Showcases CBL-514 Obesity Combination Data at ECO 2026
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
Harbour BioMed Reports Strong Preclinical Results for AI-Designed Obesity Drug LET003
CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; and SHANGHAI, China, May 18, 2026 Harbour BioMed announced promising preclinical data for LET003, its...
Advertisements
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Hanmi Expands GLP-1 Obesity Drug Reach Through Mexico Deal
SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a...
Advertisement
